Prepared Floor Remarks by U.S. Senator Chuck Grassley of Iowa
On Ensuring Brand Name Drugs Pay Brand Name Rebates
Wednesday, July 31, 2019
Not all rebates are created equal in the Medicaid Drug Rebate Program.
Rebate obligations for brand-name drugs are currently based on both brand-name and authorized generic drug sales.
That means brand-name drug manufacturers pay less in rebate obligations.
The bipartisan legislation I introduced with Senator Wyden fixes this.
It ensures that brand-name drug manufacturers pay brand-name rebates.
This reduces gaming in the system to make sure authorized generics come to market for a purpose related to patient access, not just to lower brand rebate obligations.
-30-